Biopharma and med-tech companies raising money in public or private financings, including: Bioventrix, Cingulate, Gelmedix, Levee, Liminatus, Mainz, Newron, Q32.
After 118 years as a private company, dermatology specialist Leo Pharma A/S is poised to complete an IPO after reporting a full-year net profit for the first time since 2018.
Gelmedix Inc. has completed a $13 million seed financing to support progression of the company’s lead program, GMX-101, a retinal pigment epithelial (RPE) cell therapy to treat late-stage geographic atrophy.
Beactica Therapeutics AB, together with researchers at KU Leuven, has been awarded a €2.5 million (US$3.0 million) grant by the European Innovation Council (EIC) to advance BEA-17, a precision immune therapy for glioblastoma.
Venture capital firms and research institutions have launched the European Life Science Coalition in a bid to strengthen Europe’s VC ecosystem by mobilizing more private and public investment.
Biopharma and med-tech companies raising money in public or private financings, including: Berlin Heals, Biorestorative, Entirety, Nektar, Neupulse, Neurent, Xilio.
Venture capital firms and research institutions have launched the European Life Science Coalition in a bid to strengthen Europe’s VC ecosystem by mobilizing more private and public investment.
After closing an oversubscribed $85 million series B round, Quantx Biosciences Inc. is gearing up to begin clinical trials of its two lead immunology compounds, a STAT6 oral small-molecule inhibitor and an IL-17 oral small-molecule inhibitor.
RSS
.webp?height=488&t=1770931675&width=650 "Interleukin 17 (IL-17)")